DataRobot had strong platform capability but limited access to the enterprise AI transformation conversations that start at the strategy level — the conversations where budgets get shaped and platforms get selected. BCG had exactly that access: the client relationships, the transformation credibility, and the mandate to recommend technology.
The joint GTM opportunity was clear: co-developing solutions would give DataRobot reach through BCG's deep bench of talent and client relationships, while giving BCG greater efficiency and repeatability in how they built and integrated AI into client engagements.
I was involved in building the partnership from the beginning, working with BCG's CTO, senior partners, and practice leads to design a joint working model, identify priority use cases, and create the mechanics for partners and case teams to sell jointly.
A central enabler was scale: I designed and ran a 400-person DataRobot platform training program for BCG data scientists, building the capability for their teams to build and deploy independently without requiring DataRobot involvement in every client engagement.
The first joint solution, a pharma pharmacovigilance product, was developed and sold to an initial client, validating the model. That engagement established the repeatable commercial motion: a defined client engagement approach, pass-through licensing structure, pipeline review cadence, internal BCG advocacy network, and inclusion in BCG onboarding training for new data scientists.